<DOC>
	<DOC>NCT00890903</DOC>
	<brief_summary>The purpose of this non-interventional study is to collect data on efficacy and toxicity of the use of Navelbine ORAL in daily routine in Germany (especially after availability of an 80mg capsule). The study focusses on concomitant antiemetic therapy and patient compliance.</brief_summary>
	<brief_title>Non-Interventional Study With Vinorelbine ORAL in Advanced Non-Small Cell Lung Carcinoma(NSCLC) and Metastatic Breast Cancer (MBC)</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<criteria>At least 18 years old Male and female patients Advanced NSCLC (Stage III or IV) or Antracyclineresistant MBC Therapy with Navelbine capsules in any palliative treatment line Signed patient informed consent Pregnancy and nursing All other exclusion criteria listed in SPC (summary of product characteristics) lack of signed Patient informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>non small cell lung carcinoma</keyword>
	<keyword>metastatic breast cancer</keyword>
	<keyword>MBC</keyword>
	<keyword>advanced breast cancer</keyword>
	<keyword>Navelbine</keyword>
	<keyword>Navelbine-ORAL</keyword>
	<keyword>Vinorelbine</keyword>
	<keyword>Vinorelbine-ORAL</keyword>
	<keyword>daily routine</keyword>
	<keyword>concomitant antiemetic therapy</keyword>
	<keyword>patient compliance</keyword>
	<keyword>germany</keyword>
	<keyword>non-interventional study</keyword>
	<keyword>oral anti cancer therapy</keyword>
	<keyword>quality of life</keyword>
</DOC>